Biotech | October 29, 2021
Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
